Astellas Pharma Europe LtdAddlestone, England, United Kingdom
Disclosure information not submitted.
SUN-149 - OPTION‑VMS: Preliminary Analysis of A Phase 4 Observational, Real‑World Study of Non‑Hormonal Pharmacotherapies for Bothersome Menopause‑Associated Vasomotor Symptoms and Depression and Anxiety
Sunday, June 14, 20269:00 AM - 4:00 PM CT
MON-167 - Central Nervous System Safety of Fezolinetant from Pooled Analysis of 52-Week, Phase 3 Studies (SKYLIGHT 1, 2, and 4)
Monday, June 15, 20269:00 AM - 2:00 PM CT
ORF38-03 - Central Nervous System Safety of Fezolinetant from Pooled Analysis of 52-Week, Phase 3 Studies (SKYLIGHT 1, 2, and 4)
Monday, June 15, 20269:40 AM - 9:45 AM CT
.jpg)
.jpg)